Sponsor:
University of Erlangen-Nürnberg Medical School
Collaborator:
-
Studienleiter
Vratislav Strnad, MD Study Chair University Hospital Erlangen, Dept. of Radiooncology Bastian Keck, MD Study Chair University Hospital Erlangen, Dept. of Urology Alexander Cavallaro, MD Study Chair University Hospital Erlangen, Dept. of Radiology Arndt Hartmann, MD Study Chair University Hospital Erlangen, Dept. of Pathology Michael Lotter, Dipl.-Phys. Study Chair University Hospital Erlangen, Dept. of Radiooncology Annedore Strnad, MD, MHBA Study Chair University Hospital Erlangen, Dept. of Radiooncology Peter Goebell, MD Study Chair University Hospital Erlangen, Dept. of Urology Wolfgang Uter, MD Study Chair University Erlangen; Dept. of Biometrics and Epidemiology Michael Uder, MD Study Chair University Hospital Erlangen, Dept. of Radiology Bernd Wullich, MD Study Chair University Hospital Erlangen, Dept. of Urology Rainer Fietkau, MD Study Chair University Hospital Erlangen, Dept. of Radiooncology
- Unilateral affection; index lesion ≤ 0.5ml with or without clinically non-significant
lesion contralateral. No more than 25% of the punch should be affected. Therefore a
3D-TPM-biopsy is mandatory before treatment.
- PSA ≤ 10/ng/ml
- Prostate volume < 60 m^3
- No distant metastasis
- Life expectancy > 10 years
- Informed consent
Exclusion Criteria:
- Tumor stage ≥ T2b
- Known metastasis: N+ and/or M1
- General anesthesia or peridural anesthesia is not possible
